Evelina Vågesjö

I plan to use the fellowship to create a collaborative stakeholder strategy for MDR (Multi-Drug Resistant) pathogen testing, treatment and policy reform.

"WPAB" is a fully owned subsidiary to Ilya Pharma AB and is focused on developing and marketing differentiated post biotic products for humans and animals.

Ilya Pharma 🇸🇪🇺🇸 is developing immunotherapies for the treatment of diseases in skin and mucosa. Ilya Pharma develops the next generation of biological immunotherapies using a single GMO microorganism as both factory and delivery mechanism of therapeutic, human-endogenous, proteins that cannot be developed as biologics. We are a leading-edge Swedish biopharmaceutical company founded in 2016 and now working on several break-though drug candidates currently in clinical phase I and II/III. Our proprietary technology platform allows use of therapeutic, human-endogenous, proteins that cannot be developed as biologics. The ILP-platform uses lactic acid bacteria expressing human endogenous, immunomodulative proteins which act locally in both skin and mucosal body surfaces. More exciting innovation will follow. Ilya Pharma is working to revolutionize the field of regenerative medicine, and Innumology and inflammation: In a market counting patients in the millions, our first product will accelerate wound healing - including chronic diabetes-related wounds & surgical incisions in elevated-risk patients - and will be closely followed by a second product aimed at saving lives by addressing treatment-induced enteropathies in the GI tract through a simple, locally-acting orally administered capsule.

Thesis: Exploring immune cell functions and ways to make use of them. http://uu.diva-portal.org/smash/get/diva2:951214/FULLTEXT01.pdf

BSc in management accounting. Theisis focusing on the determinants of small Swedish biotech companies with corresponding markets and how strategy is continiously forced to evolve.

Nordic BioAnalysis (NBAB) is a GMP certified contract laboratory providing a wide spectrum of chemical and microbiological services for pharma, including ATMP and gene therapy, biotech and medical device. Our heritage from product development and quality ensures a reliable batch release or accurate product characterization. We also offer microbiological and biochemical analysis, including DNA sequencing, cloning & transformation along with stability storage complying with ICH guidelines Q1A. Our work procedures and documentation follows current cGMP for pharmaceutical products and related and the ISO/IEC 17025 standard -“General requirements for the competence of testing and calibration laboratories” for Medical Devices

Studied business and management halftime in parallell to master and graduate studies in biomedicine and physiology.